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Introduction {#sec001}
============

Malnutrition is generally associated with immune dysfunction and inflammatory processes, \[[@pone.0232714.ref001]\] leading to diminished quality of life and increased mortality in patients with pulmonary disease. \[[@pone.0232714.ref002], [@pone.0232714.ref003]\] Patients with malnutrition and limited respiratory reserves often have quantitative and functional alterations in skeletal and respiratory muscles. \[[@pone.0232714.ref001], [@pone.0232714.ref004]\] Numerous indicators, including body composition, serum protein, and nutritional indices, such as nutritional risk screening \[[@pone.0232714.ref005]\] and subjective global assessment, have been used as markers to reflect nutritional status. \[[@pone.0232714.ref006]\] Among the various nutritional assessment tools, Onodera's prognostic nutritional index (PNI) \[[@pone.0232714.ref007]\] assesses serum albumin levels and total lymphocyte counts in the peripheral blood. PNI was originally proposed to assess the perioperative nutritional status and surgical risk in patients undergoing gastrointestinal surgery. Studies have shown PNI to be a versatile prognostic tool for various malignancies. \[[@pone.0232714.ref008], [@pone.0232714.ref009]\] Compared to other nutritional indexes, PNI is an index easily calculated using only serum albumin levels and lymphocyte counts and is therefore easily assessable. But the usefulness of PNI in non-cancer medical patients has not been sufficiently proven yet.

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is becoming an increasingly common diagnosis. \[[@pone.0232714.ref010]--[@pone.0232714.ref012]\] The most common etiology of NTM-PD is *Mycobacterium avium complex* pulmonary disease (MAC-PD), \[[@pone.0232714.ref013]\] which is associated with an impaired quality of life \[[@pone.0232714.ref014]\] and is difficult and costly to treat. \[[@pone.0232714.ref015]\] Recommended treatment regimens for MAC-PD include macrolides, ethambutol, and rifampin. The American Thoracic Society (ATS) guidelines recommend a 12-month treatment period for MAC-PD following sputum conversion; however, drug intolerance often limits successful therapy. \[[@pone.0232714.ref016]\] In one previous study, more than one third of MAC-PD patients discontinued their medication because of drug intolerance, and only 33% of MAC-PD patients who started treatment achieved culture conversion. \[[@pone.0232714.ref017]\]

Poor nutritional status indicated by various markers such as body mass index (BMI) and low body fat is known to be an important factor for the pathogenesis and prognosis of NTM-PD. \[[@pone.0232714.ref018]--[@pone.0232714.ref020]\] However, its clinical implications in the treatment of patients with MAC-PD have not been evaluated as a composite value.

Therefore, in this study, we aimed to evaluate whether patients with malnutrition, as defined by PNI, are at (1) higher odds of intolerance to treatment, (2) lower odds of achieving culture conversion after treatment than non-malnutrition patients, and (3) higher risk of mortality than non-malnutrition patients.

Materials and methods {#sec002}
=====================

Study design and population {#sec003}
---------------------------

This study was a retrospective cohort analysis conducted at a tertiary care hospital. The cohort included patients diagnosed with MAC-PD between May 2005 and November 2017 ([Fig 1](#pone.0232714.g001){ref-type="fig"}). Patients were selected from our retrospective NTM-PD registry based on the following criteria: MAC-PD was confirmed according to the criteria by ATS. \[[@pone.0232714.ref015]\] Initially, 861 patients diagnosed with MAC-PD were included in the study. Patients were excluded if: (1) computed tomography (CT) images at the time of diagnosis according to our institutional radiology database were not available (n = 74); (2) clinical data, including age, height, body weight, smoking history, laboratory results, and acid-fast bacilli (AFB) test results were unavailable (n = 114); (3) there was a prior diagnosis of MAC-PD (n = 2); (4) there was a history of lung transplantation (n = 4); or (5) they were infected by hepatitis B virus (n = 2) or human immunodeficiency virus (n = 2). In total, 663 patients were included in the analysis.

![Flow diagram of subjects in this study.\
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At the time of diagnosis, data on age, smoking history, laboratory test results, underlying diseases, height and weight, radiographic findings, AFB test results, and symptoms were collected from all patients. Age was categorized into two groups (age \< 65 vs. ≥ 65 years). AFB test results were categorized into three groups (negative, '1+ and 2+', and '3+ and 4+'). Radiographic findings were categorized according to the presence of cavitary lesion on CT images.

After the diagnosis of MAC-PD, data regarding laboratory test results and antibiotic therapy were collected from 306 patients who underwent antibiotic therapy. Laboratory test results at the time of treatment initiation were available from 278 patients, and culture conversion data were available from 177 patients among 193 patients who underwent antibiotic therapy for more than a year. As the recommended duration of treatment for MAC-PD is 12 months following sputum conversion, treatment duration less than 12 months was defined as treatment intolerance. Culture conversion was defined as the presence of at least three consecutive negative mycobacterial cultures from respiratory samples collected at least 4 weeks apart, in accord with the 2018 NTM-NET consensus statement \[[@pone.0232714.ref021]\]; Date of culture conversion was established based on sampling date of the first negative culture. Follow-up data including culture results and mortality were collected until October 2018. Mortality was estimated based on the date of diagnosis to death or the last follow-up. The primary outcome was all-cause mortality. Secondary outcomes were treatment intolerance and culture conversion after antibiotic treatment.

Surrogate markers for evaluation of the nutritional status {#sec004}
----------------------------------------------------------

The PNI score was calculated using the following formula at the time of MAC-PD diagnosis and treatment initiation: 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (/mm^3^). Patients were divided into malnutrition and non-malnutrition groups according to a cut-off PNI score of 45. \[[@pone.0232714.ref022]--[@pone.0232714.ref024]\]

Statistical analysis {#sec005}
--------------------

Chi-squared tests and student's t-tests were used to compare categorical and continuous variables, respectively, between the two groups. Multivariate logistic regression models with backward variable selection were used to estimate the odds ratios (ORs) for malnutrition and culture conversion while controlling potential confounding factors. Survival was estimated using the Kaplan--Meier method and compared using the log-rank test. Multivariate Cox proportional hazards models were used to investigate relationships between clinical parameters and mortality. Of the variables collected, serum albumin levels and lymphocyte counts were not included in the multiple logistic regression models because they were included in the calculation of PNI. Variables with a p-value (P) \< 0.10, as determined by the log-rank test, were included in the multivariate Cox proportional hazard ratio model. Variables included in all multivariable analysis were tested for multicollinearity. An adjusted P \< 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 25.0 (SPSS Inc., Chicago, IL, USA).

Ethics statement {#sec006}
----------------

This research protocol was approved by the Institutional Review Board / Ethics committee. (Severance Hospital, Yonsei University Health System Institutional Review Board) The requirement to obtain informed patient consent was waived because of the retrospective nature of this study.

Results {#sec007}
=======

Baseline characteristics {#sec008}
------------------------

The baseline characteristics of participants with and without malnutrition at the time of diagnosis are shown in [Table 1](#pone.0232714.t001){ref-type="table"}. Patients with malnutrition were older, predominantly male, and had a lower BMI. The malnutrition group also had a higher proportion of participants with a history of chronic kidney disease, cardiovascular, and malignancy than did the non-malnutrition group. Based on the PNI calculations, malnutrition group had lower PNIs than the non-malnutrition group (median: 38.3 vs. 50.0, P \< 0.001). Those in the malnutrition group also had a higher proportion of cavitary CT findings and positive AFB smear results. Symptomatically, the malnutrition group reported more symptoms of dyspnea, fever, and general weakness. Of 663 patients with MAC-PD, 63 died during the follow-up period. Malnutrition patients showed significantly higher mortality rates during the follow-up (P \< 0.001).

10.1371/journal.pone.0232714.t001

###### Baseline clinical characteristics of 663 patients with Mycobacterium avium complex lung disease with or without malnutrition.
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  Variables                                                                                                         All (n = 663)       Non-malnutrition (n = 527)   Malnutrition (136)   P-value
  ----------------------------------------------------------------------------------------------------------------- ------------------- ---------------------------- -------------------- ---------
  Age, years                                                                                                        64.1 ± 11.8         62.5 ± 11.6                  70.4 ± 10.8          \<0.001
  Age ≥ 65 years                                                                                                    343 (51.7%)         243 (46.1%)                  100 (73.5%)          \<0.001
  Gender, male                                                                                                      292 (44.0%)         206 (39.1%)                  86 (63.2%)           \<0.001
  BMI, kg/m^2^                                                                                                      20.5 ± 3.3          20.8 ± 3.1                   19.7 ± 3.7           \<0.001
  Smoking, pack-years                                                                                               28.8 ± 23.2         28.5 ± 25.2                  29.7 ± 15.8          0.787
  Comorbidities                                                                                                                                                                           
   Hypertension                                                                                                     235 (35.4%)         184 (34.9%)                  51 (37.5%)           0.615
   Diabetes                                                                                                         97 (14.6%)          71 (13.5%)                   26 (19.1%)           0.103
   Chronic liver disease                                                                                            43 (6.5%)           30 (5.7%)                    13 (9.6%)            0.117
   Chronic kidney disease                                                                                           33 (5.0%)           22 (4.2%)                    11 (8.1%)            0.075
   Cardiovascular disease                                                                                           93 (14.0%)          62 (11.8%)                   31 (22.8%)           0.002
   Malignancy                                                                                                       170 (25.6%)         130 (24.7%)                  40 (29.4%)           0.271
  Laboratory test                                                                                                                                                                         
   PNI[\*](#t001fn003){ref-type="table-fn"} at time of diagnosis                                                    50.0 ± 10.5         53.0 ± 9.3                   38.3 ± 5.7           \<0.001
   Lymphocyte at time of diagnosis, 1000 cells/μL                                                                   1.87 ± 1.59         2.08 ± 1.72                  1.09 ± 0.46          \<0.001
   Albumin at time of diagnosis, g/dL                                                                               4.1 ± 0.6           4.3 ± 0.4                    3.3 ± 0.5            \<0.001
   PNI[\*](#t001fn003){ref-type="table-fn"} at time of treatment initiation[^§^](#t001fn004){ref-type="table-fn"}   49.1 ± 6.6          51.0 ± 4.5                   42.1 ± 7.9           \<0.001
   Cavitary lesion on computed tomography                                                                           155 (23.4%)         113 (21.4%)                  42 (30.9%)           0.023
  AFB smear                                                                                                                                                                               0.011
   Negative                                                                                                         569 (85.8%)         463 (87.9%)                  106 (77.9%)          
   1+ or 2+                                                                                                         69 (10.4%)          48 (9.1%)                    21 (15.4%)           
   3+ or 4+                                                                                                         25 (3.8%)           16 (3.0%)                    9 (6.6%)             
  Symptoms                                                                                                                                                                                
   Cough                                                                                                            279 (42.1%)         216 (41.0%)                  63 (46.3%)           0.284
   Sputum                                                                                                           288 (43.4%)         231 (43.8%)                  57 (41.9%)           0.699
   Dyspnea                                                                                                          77 (11.6%)          42 (8.0%)                    35 (25.7%)           \<0.001
   Hemoptysis                                                                                                       107 (16.1%)         89 (16.9%)                   18 (13.2%)           0.36
   Fever                                                                                                            42 (6.3%)           20 (3.8%)                    22 (16.2%)           \<0.001
   Weakness                                                                                                         35 (5.3%)           11 (2.1%)                    12 (8.8%)            0.001
  Treatment started                                                                                                 306 (46.2%)         241 (45.7%)                  65 (47.8%)           0.700
  Treatment duration \> 12 months                                                                                   193 (29.1%)         165 (31.3%)                  28 (20.6%)           0.015
  Time from diagnosis to initiation of treatment, months                                                            12.0 ± 21.3         13.1 ± 22.5                  8.0 ± 15.3           0.096
  Follow-up period, months                                                                                          47.3 ± 33.5         50.1 ± 33.5                  36.5 ± 31.3          \<0.001
  Culture conversion within a year after treatment[^‡^](#t001fn005){ref-type="table-fn"}                            161 / 239 (67.4%)   113 / 194 (68.6%)            28 / 45 (62.2%)      0.481
  Death during follow-up                                                                                            63 (9.5%)           34 (6.5%)                    29 (21.3%)           \<0.001

Data are presented as number (%) for categorical variables and median (range) or mean ± standard deviation (SD) for continuous variables

List of Abbreviations: PNI, prognostic nutritional index; BMI, body mass index; AFB, acid-fast bacilli

\*PNI = 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (/mm^3^)

^§^PNI data at time of treatment initiation were available for 287 patients

^‡^Culture conversion data within 1 year after treatment were available for 239 patients

Variables related to treatment intolerance {#sec009}
------------------------------------------

Among 663 MAC-PD patients, 306 (46.1%) patients were treated for MAC-PD with multiple antibiotics. To evaluate the factors related to treatment intolerance, these 306 patients were stratified by treatment duration as follows ([Table 2](#pone.0232714.t002){ref-type="table"}): 113 (36.9%) patients received treatment for less than 12 months (shorter treatment group), and 193 (63.1%) patients received treatment for longer than 12 months (longer treatment group). One third of patients did not stick to the medication as scheduled.

10.1371/journal.pone.0232714.t002

###### Basic characteristics of Mycobacterium avium complex lung disease patients who started treatment according to treatment tolerance (12 months).
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  Variables                                                                                                         All (n = 306)       Treatment longer than 12 months (n = 193, 63.1%)   Treatment shorter than 12 months (n = 113, 36.9%)   P-value
  ----------------------------------------------------------------------------------------------------------------- ------------------- -------------------------------------------------- --------------------------------------------------- ----------
  Age ≥ 65 years                                                                                                    141 (46.1%)         85 (44.0%)                                         56 (49.6%)                                          0.406
  Gender, male                                                                                                      132 (43.1%)         82 (42.5%)                                         50 (44.2%)                                          0.811
  BMI, kg/m^2^                                                                                                      19.9 ± 3.3          19.8 ± 3.0                                         20.1 ± 3.8                                          0.433
  Smoking, pack-years                                                                                               34.4 ± 27.4         34.8 ± 25.7                                        33.9 ± 30.1                                         0.905
  Comorbidities                                                                                                                                                                                                                                
   Hypertension                                                                                                     92 (30.1%)          54 (28.0%)                                         38 (33.6%)                                          0.305
   Diabetes                                                                                                         44 (14.4%)          26 (13.5%)                                         18 (15.9%)                                          0.613
   Chronic liver disease                                                                                            24 (7.8%)           13 (6.7%)                                          11 (9.7%)                                           0.382
   Chronic kidney disease                                                                                           12 (3.9%)           7 (3.6%)                                           5 (4.4%)                                            0.765
   Cardiovascular disease                                                                                           39 (12.7%)          23 (11.9%)                                         16 (14.2%)                                          0.597
   Malignancy                                                                                                       71 (23.2%)          48 (24.9%)                                         23 (20.4%)                                          0.402
  Laboratory test                                                                                                                                                                                                                              
   PNI[\*](#t002fn003){ref-type="table-fn"} at time of diagnosis                                                    49.8 ± 9.0          51.7 ± 9.0                                         46.7 ± 8.0                                          \< 0.001
   Malnutrition at time of Diagnosis (PNI[\*](#t002fn003){ref-type="table-fn"} \< 45)                               67 (23.3%)          30 (16.9%)                                         37 (33.9%)                                          0.001
   PNI[\*](#t002fn003){ref-type="table-fn"} at time of treatment initiation[^§^](#t002fn004){ref-type="table-fn"}   49.1 ± 6.6          50.4 ± 5.7                                         46.9 ± 7.3                                          \< 0.001
   Malnutrition at time of treatment start[^§^](#t002fn004){ref-type="table-fn"} (PNI \< 45)                        65 / 287 (23.3%)    30 (16.9%)                                         37 (33.9%)                                          \< 0.001
  Cavitary lesion on computed tomography                                                                            112 (36.6%)         76 (39.4%)                                         36 (31.9%)                                          0.219
  AFB smear                                                                                                                                                                                                                                    0.944
   Negative                                                                                                         243 (79.4%)         153 (79.3%)                                        90 (79.6%)                                          
   1+ or 2+                                                                                                         45 (14.7%)          28 (14.5%)                                         17 (15.0%)                                          
   3+ or 4+                                                                                                         18 (5.9%)           12 (6.2%)                                          6 (5.3%)                                            
  Symptoms                                                                                                                                                                                                                                     
   Cough                                                                                                            135 (44.1%)         80 (41.5%)                                         55 (48.7%)                                          0.234
   Sputum                                                                                                           142 (46.4%)         88 (45.6%)                                         54 (47.8%)                                          0.723
   Dyspnea                                                                                                          41 (13.4%)          20 (10.4%)                                         21 (18.6%)                                          0.055
   Hemoptysis                                                                                                       59 (19.3%)          44 (22.8%)                                         15 (13.3%)                                          0.051
   Fever                                                                                                            19 (6.2%)           10 (5.2%)                                          9 (8.0%)                                            0.337
   Weakness                                                                                                         11 (3.6%)           6 (3.1%)                                           5 (4.4%)                                            0.542
  Time from diagnosis to treatment, months                                                                          12.2 ± 21.4         10.5 ± 18.9                                        14.9 ± 24.8                                         0.095
  Treatment medication                                                                                                                                                                                                                         
   Macrolide                                                                                                        298 (97.4%)         187 (96.9%)                                        111 (98.2%)                                         0.715
   Rifampin                                                                                                         299 (97.7%)         189 (97.9%)                                        110 (97.3%)                                         0.712
   Ethambutol                                                                                                       294 (96.1%)         184 (95.3%)                                        110 (97.3%)                                         0.545
   Isoniazid                                                                                                        9 (2.9%)            5 (2.6%)                                           4 (3.5%)                                            0.730
   Fluoroquinolones                                                                                                 11 (3.6%)           6 (3.1%)                                           5 (4.4%)                                            0.542
   Aminoglycosides                                                                                                  42 (13.7%)          31 (16.1%)                                         11 (9.7%)                                           0.168
   Other                                                                                                            9 (2.9%)            7 (3.6%)                                           2 (1.8%)                                            0.493
  Initial number of medications                                                                                                                                                                                                                0.472
   ≤ 2                                                                                                              7 (2.3%)            5 (2.6%)                                           2 (1.8%)                                            
   3                                                                                                                252 (82.4%)         155 (80.3%)                                        97 (85.8%)                                          
   ≥ 4                                                                                                              47 (15.4%)          33 (17.1%)                                         14 (12.4%)                                          
  Duration of treatment, months                                                                                     14.2 ± 10.1         19.5 ± 8.7                                         5.1 ± 3.9                                           \< 0.001
  Culture conversion within a year after treatment[^‡^](#t002fn005){ref-type="table-fn"}                            160 / 237 (67.5%)   113 / 177 (63.8%)                                  47 / 60 (78.3%)                                     0.040
  Death during follow-up                                                                                            27 (8.8%)           11 (5.7%)                                          16 (14.2%)                                          0.020

Data are presented as number (%) for categorical variables and median (range) or mean ± standard deviation (SD) for continuous variables

List of Abbreviations: AFB, acid-fast bacilli

\*PNI = 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (1000 cells/μL)

^§^PNI data at time of treatment initiation were available for 287 patients

^‡^Culture conversion data within 1 year after treatment were available for 237 patients

Most patients were treated with macrolides (97.4%), rifampin (97.7%), ethambutol (96.1%), and aminoglycosides (13.7%). Drugs such as isoniazid (2.9%) and fluoroquinolones (3.6%) were less frequently used. The mean treatment duration was 14.2 ± 10.1 months overall, with a mean duration of 5.1 ± 3.9 and 19.5 ± 8.7 months in the shorter and longer treatment groups, respectively. Patients in the shorter treatment group had lower PNI scores at either the time of diagnosis or treatment initiation and showed higher culture conversion rates and mortality rates during the follow up.

[Table 3](#pone.0232714.t003){ref-type="table"} shows the relationship between malnutrition and treatment intolerance in the logistic regression models. When age (\> 65 years), gender, symptoms of dyspnea, hemoptysis, and malnutrition were included in the regression model, malnutrition (OR: 2.559, 95% confidence interval \[CI\]: 1.414--4.634, P = 0.002) was significantly related to treatment intolerance.

10.1371/journal.pone.0232714.t003

###### Multivariate logistic regression analyses for variables related to treatment intolerance.
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  Variables                                                                            OR (95% CI)            P-value
  ------------------------------------------------------------------------------------ ---------------------- ---------
  Age ≥ 65 years                                                                       1.147 (0.677--1.942)   0.611
  Gender, Male                                                                         0.820 (0.475--1.414)   0.475
  Dyspnea                                                                              1.522 (0.738--3.139)   0.255
  Hemoptysis                                                                           0.557 (0.284--1.094)   0.089
  Malnutrition, treatment initiation (PNI[\*](#t003fn002){ref-type="table-fn"} \<45)   2.559 (1.414--4.634)   0.002

List of Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; AFB, acid-fast bacilli; PNI, prognostic nutritional index

\*PNI = 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (1000 cells/μL)

Variables related to culture conversion {#sec010}
---------------------------------------

To evaluate the factors related to culture conversion, patients who received treatment longer than a year and whose culture conversion data were available were stratified by culture conversion ([Table 4](#pone.0232714.t004){ref-type="table"}). Among the 193 patients who received treatment longer than 12 months, culture conversion data were available for 177 patients. Among these 177 patients, culture conversion was achieved in 113 patients (63.8%). Patients who failed culture conversion were more likely to be male, have a shorter time span between diagnosis and treatment, have a lower BMI, and be treated longer. However, malnutrition at the time of diagnosis or treatment initiation did not significantly correlate with culture conversion.

10.1371/journal.pone.0232714.t004

###### Basic characteristics of Mycobacterium avium complex lung disease patients who received treatment longer than 12 months according to conversion failure[\*](#t004fn003){ref-type="table-fn"}.
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  Variables                                                                                                         All (n = 177)   Conversion achieved (n = 113)   Conversion failure (n = 64)   P-value
  ----------------------------------------------------------------------------------------------------------------- --------------- ------------------------------- ----------------------------- ---------
  Age ≥ 65 years                                                                                                    79 (44.6%)      47 (41.6%)                      32 (50.0%)                    0.345
  Gender, male                                                                                                      74 (41.8%)      38 (33.6%)                      36 (56.3%)                    0.004
  BMI, kg/m^2^                                                                                                      19.7 ± 3.0      19.9 ± 3.1                      19.4 ± 2.8                    0.301
  Smoking, pack-years                                                                                               34.6 ± 26.4     37.0 ± 32.4                     32.6 ± 20.7                   0.625
  Time from diagnosis to treatment, months                                                                          10.6 ± 18.9     13.5 ± 22.2                     5.4 ± 8.7                     0.009
  Comorbidities                                                                                                                                                                                   
   Hypertension                                                                                                     51 (28.8%)      33 (29.2%)                      18 (28.1%)                    1.000
   Diabetes                                                                                                         24 (13.6%)      18 (15.9%)                      6 (9.4%)                      0.260
   Chronic liver disease                                                                                            13 (7.3%)       7 (6.2%)                        6 (9.4%)                      0.550
   Chronic kidney disease                                                                                           6 (3.4%)        4 (3.5%)                        2 (3.1%)                      1.000
   Cardiovascular disease                                                                                           20 (11.3%)      10 (8.8%)                       10 (15.6%)                    0.217
   Malignancy                                                                                                       45 (25.4%)      31 (27.4%)                      14 (21.9%)                    0.475
  Laboratory test                                                                                                                                                                                 
   PNI[\*](#t004fn003){ref-type="table-fn"} at time of diagnosis                                                    51.8 ± 9.2      52.9 ± 9.7                      49.9 ± 6.6                    0.033
   Malnutrition at time of Diagnosis (PNI[\*](#t004fn003){ref-type="table-fn"} \< 45)                               25 (14.1%)      12 (10.6%)                      13 (20.3%)                    0.114
   PNI[\*](#t004fn003){ref-type="table-fn"} at time of treatment initiation[^‡^](#t004fn005){ref-type="table-fn"}   50.4 ± 5.7      50.7 ± 5.2                      49.8 ± 6.6                    0.351
   Malnutrition at time of treatment start[^‡^](#t004fn005){ref-type="table-fn"} (PNI \< 45)                        28 (15.8%)      14 (12.3%)                      14 (21.9%)                    0.079
  Cavitary lesion on computed tomography                                                                            71 (40.1%)      39 (34.%)                       32 (50.0%)                    0.055
  AFB smear                                                                                                                                                                                       0.015
   Negative                                                                                                         142 (80.2%)     98 (86.7%)                      44 (68.8%)                    
   1+ or 2+                                                                                                         24 (13.6%)      10 (8.8%)                       14 (21.9%)                    
   3+ or 4+                                                                                                         11 (6.2%)       5 (4.4%)                        6 (9.4%)                      
  Symptoms                                                                                                                                                                                        
   Cough                                                                                                            75 (42.4%)      45 (39.8%)                      30 (46.9%)                    0.429
   Sputum                                                                                                           80 (45.2%)      47 (41.6%)                      33 (51.6%)                    0.212
   Dyspnea                                                                                                          20 (11.3%)      12 (10.6%)                      8 (12.5%)                     0.806
   Hemoptysis                                                                                                       39 (22.0%)      23 (20.4%)                      16 (25.0%)                    0.572
   Fever                                                                                                            10 (5.6%)       8 (7.1%)                        2 (3.1%)                      0.333
   Weakness                                                                                                         6 (3.4%)        6 (5.3%)                        0 (0.0%)                      0.088
  Treatment medication                                                                                                                                                                            
   Macrolide                                                                                                        173 (97.7%)     110 (97.3%)                     63 (98.4%)                    1.000
   Rifampin                                                                                                         174 (98.3%)     111 (98.2%)                     63 (98.4%)                    1.000
   Ethambutol                                                                                                       170 (96.0%)     111 (98.2%)                     59 (92.2%)                    0.100
   Isoniazid                                                                                                        3 (1.7%)        3 (2.7%)                        0 (0.0%)                      0.554
   Fluoroquinolones                                                                                                 6 (3.4%)        2 (1.8%)                        4 (6.3%)                      0.191
   Aminoglycosides                                                                                                  29 (16.4%)      15 (13.3%)                      14 (21.9%)                    0.145
   Other                                                                                                            4 (2.3%)        1 (0.9%)                        3 (4.7%)                      0.135
  Initial number of medications                                                                                                                                                                   0.648
   ≤ 2                                                                                                              5 (2.8%)        3 (2.7%)                        2 (3.1%)                      
   3                                                                                                                142 (80.2%)     93 (82.3%)                      49 (76.6%)                    
   ≥4                                                                                                               30 (16.9%)      17 (15.0%)                      13 (20.3%)                    
  Duration of treatment, months                                                                                     20.5 ± 9.8      16.9 ± 4.8                      24.0 ± 11.3                   \<0.001

Data are presented as number (%) for categorical variables and median (range) or mean ± standard deviation (SD) for continuous variables

List of Abbreviations: PNI, prognostic nutritional index; BMI, body mass index; AFB, acid-fast bacilli

\*PNI = 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (/mm^3^)

^§^Among the 193 patients who received treatment longer than 12 months, culture conversion data were available for 177 patients

^‡^Among the 193 patients who received treatment longer than 12 months, PNI data at the time of treatment initiation were available for 178 patients

[S1 Table](#pone.0232714.s001){ref-type="supplementary-material"} shows the relationship between malnutrition and culture conversion failure in the multivariate logistic regression models. When age, gender, cavitary lesion on CT, AFB smear result, time from diagnosis to treatment, and malnutrition at the time of treatment were included in the regression model, malnutrition (OR: 1.288, 95% CI: 0.630--2.637, P = 0.488) was not significantly related to culture conversion failure.

Variables related to all-cause mortality {#sec011}
----------------------------------------

Kaplan-Meier survival curves stratified by malnutrition and non-malnutrition groups at the time of diagnosis are shown in [Fig 2](#pone.0232714.g002){ref-type="fig"}. Patients in the malnutrition group exhibited a significantly higher mortality rate (P \< 0.001) than those in the non-malnutrition group. The relationships between all-cause mortality and clinical parameters, including malnutrition, were evaluated in [Table 5](#pone.0232714.t005){ref-type="table"}. Univariate analysis revealed that age ≥ 65 years, male gender, lower BMI, malnutrition at the time of diagnosis (P \< 0.001), treatment shorter than 12 months, and history of diabetes, chronic kidney disease, cardiovascular disease, and cancer were correlated significantly with all-cause mortality. Comparison of the contributions of these indices by multivariate Cox proportional hazards analyses demonstrates that malnutrition (hazard ratio: 2.755, 95% CI: 1.610--4.475, P \< 0.001), age ≥ 65 years, male gender, lower BMI, history of cancer, and positive AFB smear were significant risk factors for all-cause mortality.

![Kaplan--Meier survival curves stratified by nutritional status.\
Patients were divided into malnutrition and non-malnutrition groups according to prognostic nutritional index\*. \*Cut-off value of prognostic nutritional index for defining malnutrition and non-malnutrition was 45. List of Abbreviations; MAC, Mycobacterium avium complex.](pone.0232714.g002){#pone.0232714.g002}

10.1371/journal.pone.0232714.t005

###### Univariate and multivariate Cox's proportional hazard analyses of factors for mortality in Mycobacterium avium complex lung disease patients.

![](pone.0232714.t005){#pone.0232714.t005g}

  Variables                                  Among the deaths (n = 63)   Univariate             Multivariate                          
  ------------------------------------------ --------------------------- ---------------------- -------------- ---------------------- ---------
  Age, years                                 69.6 ± 10.7                 1.060 (1.033--1.086)   \<0.001                               
  Age ≥ 65 years                             46 (73.0%)                  2.960 (1.692--5.179)   \<0.001        2.044 (1.075--3.887)   0.029
  Sex, male                                  46 (73.0%)                  3.792 (2.170--6.626)   \<0.001        2.534 (1.376--4.664)   0.003
  Body mass index, kg/m^2^                   19.0 ± 3.6                  0.854 (0.786--0.927)   \<0.001        0.858 (0.786--0.937)   0.001
  Smoking, pack-years                        32.2 ± 19.3                 1.006 (0.990--1.023)   0.465                                 
  NTM type, with cavity                      18 (28.6%)                  1.299 (0.751--2.248)   0.349                                 
  AFB smear                                                                                                                           
   Negative                                  43 (68.3%)                  Reference                             Reference              
   1+ or 2+                                  14 (22.2%)                  3.151 (1.705--5.822)   \<0.001        2.849 (1.493--5.437)   0.001
   3+ or 4+                                  6 (9.5%)                    2.380 (0.981--5.775)   0.055          2.477 (0.999--6.139)   0.050
  Malnutrition, Diagnosis (PNI \< 45)        29 (46.0%)                  4.421 (2.686--7.277)   \<0.001        2.755 (1.610--4.715)   \<0.001
  PNI, diagnosis                             44.5 ± 10.4                 0.906 (0.880--0.932)   \<0.001                               
  Treatment started                          27 (42.9%)                  0.644 (0.388--1.071)   0.090          0.496 (0.288--0.854)   0.011
  Treatment longer than 12 months            11 (17.5%)                  0.356 (0.185--0.686)   0.002                                 
  Treatment duration, months                 10.7 ± 8.2                  0.941 (0.896--0.989)   0.016                                 
  Time from diagnosis to treatment, months   6.9 ± 20                    1.009 (0.979--1.039)   0.576                                 
  Hypertension                               30 (47.6%)                  1.560 (0.951--2.560)   0.078          1.140 (0.629--2.067)   0.665
  Diabetes                                   16 (25.4%)                  1.950 (1.105--3.441)   0.021          1.348 (0.723--2.514)   0.347
  Chronic liver disease                      2 (3.2%)                    0.410 (0.100--1.678)   0.215                                 
  Chronic kidney disease                     6 (9.5%)                    2.209 (0.950--5.140)   0.066          1.701 (0.685--4.227)   0.253
  Cardiovascular disease                     16 (25.4%)                  1.987 (1.121--3.520)   0.019          1.363 (0.718--2.590)   0.344
  Cancer                                     31 (49.2%)                  2.841 (1.731--4.664)   \<0.001        2.477 (0.999--6.139)   0.001

List of Abbreviations: HR, hazards ratio; 95% CI, 95% confidence interval; BMI, body mass index; PNI, prognostic nutritional index;

\*PNI = 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (1000 cells/μL)

Discussion {#sec012}
==========

Poor nutritional status represented by low BMI, low fat composition, and low level of serum albumin were reported as risk factors of progression of NTM PD. \[[@pone.0232714.ref025]--[@pone.0232714.ref027]\] Thus, experts recommend the treatment of MAC-PD when patients with considerable burden of disease (e.g., cavitary lesion on chest CT, AFB smear positive) have a poor nutritional status. However, the impact of poor nutritional status on the treatment outcome of MAC-PD has not been well evaluated.

To our knowledge, this is the first study to demonstrate the clinical utility of analyzing the relationship between PNI (as a composite value of malnutrition) and outcomes of MAC-PD. All-cause mortality was significantly higher in the malnutrition group than in the non-malnutrition group as defined by PNI at the time of diagnosis. Treatment intolerance, but not culture conversion rates after antibiotic therapy, was also related with malnutrition as defined by PNI at the time of treatment initiation. In addition, symptoms such as dyspnea, fever, and weakness were more common in patients with malnutrition than those in the non-malnutrition group. This may explain the relationship between malnutrition and treatment intolerance and mortality, as well as quality of life.

In this study, patients were divided into malnutrition and non-malnutrition groups according to the cut-off PNI score of 45, which has been reported to indicate moderate-to-severe malnutrition. \[[@pone.0232714.ref024]\] Conversely, in previous studies, the PNI cut-off value for defining malnutrition varied between 40.0 and 50.0. \[[@pone.0232714.ref028]--[@pone.0232714.ref030]\] The optimal cut-off value and the division of the groups by PNI remain unclear. Further studies including prospective studies are needed to clarify the cut-off point not only for MAC-PD patients but for general non-surgical patients.

Numerous indicators have been used as markers to reflect nutritional status. Nutritional risk screening \[[@pone.0232714.ref005]\] uses information regarding food intake, BMI, and weight loss. Subjective global assessment \[[@pone.0232714.ref006]\] is a more detailed assessment that comprises patient history, as well as physical and subjective global assessment-specified variables. BMI is a well-known nutritional indicator; however, BMI distribution differs greatly across racial and ethnic populations. The nutritional status score \[[@pone.0232714.ref031]\] is calculated using serum cholesterol, lymphocyte, and albumin, and the Glasgow prognostic score \[[@pone.0232714.ref032]\] is calculated using albumin and C-reactive protein. In comparison, as mentioned before, PNI is calculated using only serum albumin levels and lymphocyte counts. PNI is therefore an easy and reliable tool with minor variability. \[[@pone.0232714.ref033]\]

PNI is known to reflect the nutritional and immune condition of patients. \[[@pone.0232714.ref023]\] Malnutrition reduces albumin concentration by decreasing its rate of synthesis; similarly, inflammation increases fractional catabolic rate, and in severe circumstances, it increases the permeability of vasculature, thereby allowing albumin to leak out into the extravascular space. \[[@pone.0232714.ref034]\] Furthermore, Siedner et al. reported that low serum albumin levels were strongly correlated with higher levels of the inflammatory marker interleukin 6, thus possibly indicating that low albumin levels might be a consequence of immune activation through mechanisms less directly associated with interleukin 6. \[[@pone.0232714.ref035]\] Malnutrition also results in lymphocyte deficiency. Chandra et al. \[[@pone.0232714.ref036]\] reported that patients with malnutrition had reduced lymphocyte counts. Lymphocytes are important to humoral immunity as well as cell-mediated immunity. \[[@pone.0232714.ref037], [@pone.0232714.ref038]\]

Malnutrition is reported to be risk factor of progression of NTM-PD, \[[@pone.0232714.ref025]--[@pone.0232714.ref027]\] and the outcome of mycobacterial infections is dependent on the interaction between the bacteria and the host's immune system. \[[@pone.0232714.ref039]\] Considering that PNI reflects both nutritional and immune status, low PNI scores could act as risk factors for the progression of MAC-PD. PNI scores may decrease because of advanced inflammation of MAC-PD and thus be related with higher mortality.

Treatment intolerance is particularly important in the treatment of MAC-PD. In the existing guideline, considerations on whether to start treatment, the age, baseline disease status, and risk benefit assessment of treatment effect and side effect are essential. In our study, one third of patients who initiated multiple antibiotics treatment discontinued the medication, as previously reported. \[[@pone.0232714.ref017]\] PNI was meaningful in predicting drug intolerance in our study. Further consideration of PNI may help predict drug intolerance and manage patients with MAC-PD.

Previous studies have demonstrated that nutritional interventions can improve a patient's lymphocyte \[[@pone.0232714.ref036]\] and albumin levels. \[[@pone.0232714.ref040]\] Nutritional support, therefore, may result in higher PNI scores. As our study demonstrated that higher PNI scores are related with better outcomes, nutritional interventions for MAC-PD might be helpful for patients with low PNI scores.

This study has some limitations. First, the study was retrospective and only included samples from a single center with limited number of patients and involved no replication cohort. Although multivariate analyses were performed, there are many compounding factors that influence the treatment and prognosis of MAC-PD. However, the validity of reported prognostic factors, such as BMI, and history of cancer or diabetes, was confirmed in this study population, thereby lending support to the present findings. Secondly, other methods of evaluating malnutrition other than BMI were not available at the time of our analysis. Integrating and comparing other indexes in future studies may help to further comprehend the nature and prognosis of MAC-PD. Thirdly, although PNI has been proposed as a simple surrogate marker for evaluating immune-nutritional status, serum albumin levels and lymphocyte counts could also be influenced by a number of other factors, including medications, underlying disease, time, and age. \[[@pone.0232714.ref001]\]

Conclusion {#sec013}
==========

In the present study, we found that malnutrition, as defined by PNI, is a risk factor for all-cause mortality in MAC-PD patients. Treatment intolerance during antibiotic therapy was significantly higher in patients with malnutrition than in those in the non-malnutrition group. These findings suggest that the PNI score, which can be easily calculated using serum albumin levels and lymphocyte counts, is a useful prognostic marker for mortality and treatment intolerance. It is important to stress the importance of nutritional assessment for patients with MAC-PD.

Supporting information {#sec014}
======================

###### Multivariate logistic regression analyses for variables related to culture conversion failure.

(DOCX)

###### 

Click here for additional data file.

###### Data set for MAC-PD study.

(XLSX)

###### 

Click here for additional data file.
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1, The authors concluded that malnutrition as defined by PNI is an independent predictor for treatment intolerance and all-cause mortality in patients with MAC-PD.

In table 1, there are many differences in the background between non-malnutrition group and malnutrition group. Although the authors performed a multivariate analysis, first of all, can malnutrition be an independent factor because there are so many compounding factors.

As you know, it is natural that patients with malnutrition are high age, easy to discontinue the treatment of MAC-PD, and therefore, they have poor prognosis.

The impact of the primary outcome in this study may be slightly weak.

2, As the disease of MAC-PD progresses, the nutrition status will get worsens.

I doubt that the patients with malnutrition group had more severe MAC-PD compared to non-malnutrition group. I think that the description regarding the status of the MAC-PD at diagnosis is poor.

Reviewer \#3: This study evaluated the impact of PNI on outcomes in patients with MAC PD.
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Point by Point response to the editor

Reviewer \#1

1\. Authors reported useufullness of PNI in MAC-PD patients. Low PNI patients failed treatment and showed poor prognosis. Cut-off value of PNI should be calculated by ROC cureve or other methods. However, cut-off value of PNI was determined by other reports.

Reply: Thank you for kind advice. Additionally, we tried receiver operating characteristic (ROC) curve for mortality to calculate the cut-off of PNI.

The cut-off was 46.2 (Sensitivity 57.14, Specificity 77.53, AUC 0.698, P \< 0.001). When using this cut-off, Multivariate logistic regression analyses for variables related to treatment intolerance (Table 3), Multivariate logistic regression analyses for variables related to culture conversion failure (S1 Table), and multivariate Cox's proportional hazard analyses of factors for mortality in Mycobacterium avium complex lung disease patients (part of Table 5) changed as follows.

Table 3. Multivariate logistic regression analyses for variables related to treatment intolerance

Variables OR (95% CI) P-value

Age ≥ 65 years 1.367 (0.950-1.969) 0.092

Gender, Male 0.847 (0.586-1.225) 0.377

Dyspnea 0.907 (0.515-1.598) 0.735

Hemoptysis 0.547 (0.353-0.847) 0.547

Malnutrition, treatment initiation (PNI \<46.2) 1.866 (1.186-2.937) 0.007

S1 Table. Multivariate logistic regression analyses for variables related to culture conversion failure

Variables OR (95% CI) P-value

Age ≥ 65 years 1.135 (0.587-2.194) 0.707

Gender, Male 1.246 (0.628-2.474) 0.529

Cavitary lesion on computed tomography 1.415 (.0746-2.685) 0.288

Positive AFB Smear 2.350 (1.069-5.163) 0.033

Time from diagnosis to treatment, months 0.981 (0.961-1.002) 0.081

Malnutrition (PNI\* \<45) 1.236 (0.595-2.567) 0.571

Table 5. Univariate and multivariate Cox's proportional hazard analyses of factors for mortality in Mycobacterium avium complex lung disease patients

Variables Multivariate

HR (95% CI) P-value

Age ≥ 65 years 1.908 (0.998-3.649) 0.051

Sex, male 2.379 (1.289-4.393) 0.006

Body mass index, kg/m2 0.866 (0.793-0.946) 0.001

Positive AFB smear 2.838 (1.576-5.111) 0.001

Malnutrition, Diagnosis (PNI \< 46.2) 2.812 (1.623-4.872) \<0.001

Treatment started 0.559 (0.321-0.973) 0.040

Hypertension 1.208 (0.659-2.215) 0.542

Diabetes 1.356 (0.726-2.567) 0.350

Chronic kidney disease 1.709 (0.682-4.277) 0.253

Cardiovascular disease 1.218 (0.630-2.355) 0.558

Cancer 2.443 (1.410-4.233) 0.001

As we could see from the results above, that low PNI is a risk factor for mortality and treatment intolerance did not change and consistent reliability of PNI in MAC-PD was confirmed. But the problem of using ROC curve in defining cut-off is that through the paper, we wanted to analyze not only mortality but intolerance and treatment response and thought that using multiple cut-off could only cause confusion. Also, the cut-off of 45 was used as the cut-off 45 was not verified in MAC-PD patients. But we believe that through prospective study on MAC-PD patients, clarifying a new cut-off for malnutrition is needed. The sentence in discussion section has been changed. (Page 15, line 18-19)

Reviewer \#2

This study is a retrospective cohort analysis to evaluate whether patients with malnutrition, as defined by PNI, are high odds of intolerance to treatment, lower odds of achieving culture conversion after treatment, and higher risk of mortality than non-malnutrition patients.

I think this study is very interesting because this is the first study to analysis the relationship between PNI and outcome of MAC-PD.

I would like to request some revisions to make the article more sophisticated.

Reply: We appreciate your kind review.

1\. The authors concluded that malnutrition as defined by PNI is an independent predictor for treatment intolerance and all-cause mortality in patients with MAC-PD.

In table 1, there are many differences in the background between non-malnutrition group and malnutrition group. Although the authors performed a multivariate analysis, first of all, can malnutrition be an independent factor because there are so many compounding factors.

As you know, it is natural that patients with malnutrition are high age, easy to discontinue the treatment of MAC-PD, and therefore, they have poor prognosis.

The impact of the primary outcome in this study may be slightly weak.

Reply: We totally agree with your valuable advice. But as the prevalence of MAC-PD is low and due to the retrospective nature of the study, we could not match variables nor add more variables due to limited number of patients. This paper was first written in 2017 but was delayed to additionally recruit patient data. We tried univariate Cox regression analysis first and then put the meaningful variables in the multivariate analysis in the analysis, as you mentioned, to identify whether malnutrition can be an independent factor excluding many compounding factors. And we also checked the multicollinearity between the variables. We tried using the term 'related' rather than 'associated' and the remaining term 'associated' was changed into 'related' and added the point the reviewer pointed in the limitation part. (Page 15, line 11 and Page 17, line 6-8)

2\. As the disease of MAC-PD progresses, the nutrition status will get worsens.

I doubt that the patients with malnutrition group had more severe MAC-PD compared to non-malnutrition group. I think that the description regarding the status of the MAC-PD at diagnosis is poor.

Reply: Thank you for your wise advice. Until now, there is no authorized way to evaluate MAC-PD\'s severity, but currently, the presence of cavitary lesion on chest CT and sputum AFB smears are frequently used to examine the severity of MAC-PD in the practice. In our analysis, we included the presence of cavitary lesion on chest CT. And about the AFB smear, it was included in the analysis, but AFB smear was only categorized into positive or negative. To give additional data on the status of MAC-PD at diagnosis, the AFB status was additionally categorized into "negative", "1+ and 2+", and "3+ and 4+". We wish this could give additional data on the severity of MAC-PD. Analyses were performed again and the numbers in the paper have changed accordingly. (Abstract, Result section, Tables, S1 Table) 

Reviewer \#3

This study evaluated the impact of PNI on outcomes in patients with MAC PD.

The manuscript was well written.

I have only a few comments.

Reply: We appreciate your kind review.

Major

1\. In Introduction section, please add the reason why you chose to evaluate PNI among the various nutrition assessment tools in this study.

Reply: Thank you for your valuable advice. We additionally added the reason why we chose to evaluate PNI among the various nutrition assessment tools from discussion to introduction section. (Page 3, line 6-7)

Minor

1\. page 12 line 11 \"Based off\" →　You mean \"Based on\" ？

Reply: Thank you for your correction. We have changed "Based off" to "Based on". (Page 6, line 14)

###### 

Submitted filename: Response to the reviewers.docx

###### 

Click here for additional data file.
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